Filing Flows › Comparisons › PBYI vs TNGX
Puma Biotechnology vs Tango Therapeutics: PBYI and TNGX compared
Puma Biotechnology is the larger company: $55.1M of revenue in its latest quarter (Q3 2026) against $53.8M for Tango Therapeutics (Q3 2025). Tango Therapeutics is growing faster (+364% against +1% a year earlier). Tango Therapeutics is more profitable, with an operating margin of 26.2% against 9.6%.
Where the money goes: PBYI and TNGX
Puma Biotechnology (PBYI) · Q3 2026
Puma Biotechnology, Q3 2026: revenue $55.1M (+1% year over year), operating margin 9.6%, net earnings $6.0M. The chart follows the revenue to costs, profit and cash.
Tango Therapeutics (TNGX) · Q3 2025
Tango Therapeutics, Q3 2025: revenue $53.8M (+364% year over year), operating margin 26.2%, net earnings $15.9M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
| Puma Biotechnology (PBYI) | Tango Therapeutics (TNGX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2025 |
| Revenue | $55.1M | $53.8M |
| Revenue growth, Y/Y | +1% | +364% |
| Operating margin | 9.6% | 26.2% |
| Net earnings | $6.0M | $15.9M |
| Net margin | 10.9% | 29.5% |
| Operating cash flow | — | −$31.0M |
Where the revenue comes from
Puma Biotechnology
- Product revenue, net: $54.1M (98%)
- Royalty revenue: $1.0M (2%)
Questions
Which is bigger, Puma Biotechnology or Tango Therapeutics?
Puma Biotechnology is the larger company: $55.1M of revenue in its latest quarter (Q3 2026) against $53.8M for Tango Therapeutics (Q3 2025).
Is Puma Biotechnology or Tango Therapeutics growing faster?
Tango Therapeutics is growing faster (+364% against +1% a year earlier).
Which is more profitable, Puma Biotechnology or Tango Therapeutics?
Tango Therapeutics is more profitable, with an operating margin of 26.2% against 9.6%.
More: Puma Biotechnology earnings · how Puma Biotechnology makes money · Tango Therapeutics earnings · how Tango Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (8-K filed Nov 5, 2026; 10-Q filed Nov 4, 2025). Fiscal quarters can end on different dates. Not investment advice.